Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6-11 Years of Age with Severe Atopic Dermatitis.

Dermatology and therapy（2023）

引用 0|浏览5

暂无评分

摘要

ClinicalTrials.gov Identifier NCT02612454.

查看译文

关键词

Atopic dermatitis, Children, Dupilumab, Eczema, Efficacy, Long-term, Open-label, Pediatric, Quality of life, Safety

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要